• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
FinanceInsys Therapeutics

Pharma Billionaire Arrested On Charges of Bribing Doctors to Prescribe Opioid Painkillers

Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
October 26, 2017, 5:56 PM ET

The same day President Donald Trump declared the opioid crisis a nationwide public health emergency, the federal government said it arrested a wealthy pharmaceutical company executive on charges of bribing doctors to needlessly prescribe his firm’s opioid painkiller.

The Department of Justice arrested Insys Therapeutics founder John Kapoor, 74, in Phoenix, it said Thursday. Kapoor was charged with using bribes and fraud to prop up sales of a pain medication called Subsys, a fentanyl spray typically used to treat cancer patients suffering excruciating pain.

University at Buffalo/ReutersUniversity at Buffalo/Reuters
University at Buffalo/Reuters

Kapoor’s arrest comes nearly a year after former Insys CEO Michael Babich and five other onetime executives were arrested as part of an alleged “nationwide conspiracy.”

The Justice Department claims that Kapoor and other Insys executives offered bribes in the form of kickbacks to doctors who wrote “large numbers of prescriptions” for patients, many of whom did not have cancer. The Department also alleged that the executives defrauded insurers by forming a “reimbursement unit” dedicated to obtaining prior authorization from insurers who were reluctant to pay for the drug.

“These Insys executives allegedly fueled the opioid epidemic by paying doctors to needlessly prescribe an extremely dangerous and addictive form of fentanyl,” Phillip Coyne, special agent in charge for the Office of Inspector General of the U.S. Department of Health and Human Services, said in a press release.

“The allegations of selling a highly addictive opioid cancer pain drug to patients who did not have cancer, make them no better than street-level drug dealer,” added Harold Shaw, a Federal Bureau of Investigation special agent.
Insys did not immediately return Fortune’s request for comment.

Insys’ stock closed down nearly 23% following the news of Kapoor’s arrest, pushing the company’s valuation down to $417 million. It was a stunning retreat, considering the company was valued at over $19 billion as recently as 2015, when concerns about the company’s practices were first raised. (Insys is now also developing its own drug to reverse opioid overdoses.)

Insys’ falloff has cost Kapoor a hefty portion of his own net worth, which is made up in part of company stock. At Insys’ peak, Kapoor’s current stake in the company was worth over $1.9 billion. By Thursday’s close, it was down to $246.7 million. (Kapoor still holds a $1 billion stake in Akorn Pharmaceuticals, a generic drug maker where he also serves as board chairman. Akorn’s stock was down about 1% at Thursday’s close.)
Kapoor is set to make a court appearance in Phoenix at a later date.
About the Author
Lucinda Shen
By Lucinda Shen
See full bioRight Arrow Button Icon

Latest in Finance

Travel & LeisureBrainstorm Design
Luxury hotels need to have ‘a point of view’ to attract visitors hungry for experiences, says designer André Fu
By Nicholas GordonDecember 4, 2025
2 hours ago
Personal FinanceCertificates of Deposit (CDs)
Best certificates of deposit (CDs) for December 2025
By Glen Luke FlanaganDecember 4, 2025
7 hours ago
The Fifth Third Bank logo on a blue and purple layered background.
Personal Financechecking accounts
Fifth Third Bank review 2025: Full-service bank with unique perks (but lackluster APYs)
By Joseph HostetlerDecember 4, 2025
7 hours ago
Trump
PoliticsWhite House
‘We fixed inflation, and we fixed almost everything’: Trump travels to Pennsylvania to talk affordability while denying it’s a problem
By Josh Boak and The Associated PressDecember 4, 2025
7 hours ago
Bear
RetailTariffs and trade
Build-A-Bear stock falls 15% as it reveals the real hit from tariffs, at last
By Michelle Chapman and The Associated PressDecember 4, 2025
8 hours ago
Gen Z
EconomyGen Z
America, meet your alienated youth: ‘Gold standard’ Harvard survey reveals Gen Z’s anxiety and distrust, defined by economic insecurity
By Nick LichtenbergDecember 4, 2025
8 hours ago

Most Popular

placeholder alt text
Economy
Two months into the new fiscal year and the U.S. government is already spending more than $10 billion a week servicing national debt
By Eleanor PringleDecember 4, 2025
17 hours ago
placeholder alt text
Success
‘Godfather of AI’ says Bill Gates and Elon Musk are right about the future of work—but he predicts mass unemployment is on its way
By Preston ForeDecember 4, 2025
12 hours ago
placeholder alt text
North America
Jeff Bezos and Lauren Sánchez Bezos commit $102.5 million to organizations combating homelessness across the U.S.: ‘This is just the beginning’
By Sydney LakeDecember 2, 2025
3 days ago
placeholder alt text
Success
Nearly 4 million new manufacturing jobs are coming to America as boomers retire—but it's the one trade job Gen Z doesn't want
By Emma BurleighDecember 4, 2025
13 hours ago
placeholder alt text
Success
Nvidia CEO Jensen Huang admits he works 7 days a week, including holidays, in a constant 'state of anxiety' out of fear of going bankrupt
By Jessica CoacciDecember 4, 2025
12 hours ago
placeholder alt text
Health
Bill Gates decries ‘significant reversal in child deaths’ as nearly 5 million kids will die before they turn 5 this year
By Nick LichtenbergDecember 4, 2025
24 hours ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.